U.S., Oct. 8 -- ClinicalTrials.gov registry received information related to the study (NCT07209865) titled '68Ga-P16-093 PET Imaging for Diagnosing Prostate Cancer, a Head-to-head Comparison With mpMRI' on Sept. 30.
Brief Summary: 68Ga-P16-093 is a novel radiotracer targeting PSMA. In this study, we investigated the diagnostic efficacy of 68Ga-P16-093 PET imaging (PET/CT or PET/MRI) in patients with newly diagnosed, treatment-naive prostate cancer, and performed a head-to-head comparison with multi-parameter magnetic resonance imaging (mpMRI).
Study Start Date: Oct. 01, 2024
Study Type: INTERVENTIONAL
Condition:
Prostate Cancer (Adenocarcinoma)
Intervention:
DRUG: 68Ga-P16-093
Intravenous injection of Ga-P16-093 with a dosage of 111...